未经证实:为了描述晚发型类风湿关节炎(LORA)与青年型(YORA)之间的患者特征,并分析其与累积炎症负担的关系。
UASSIGNED:我们在一项前瞻性队列中进行了嵌套队列研究,该队列包括110例类风湿关节炎(RA)患者和110例年龄和性别匹配的对照。主要变量是根据28关节疾病活动评分和红细胞沉降率(DAS28-ESR)的累积炎症活动。高活性定义为DAS28≥3.2,低活性定义为DAS28<3.2。记录的其他变量是炎症细胞因子,物理功能,和合并症条件。运行两个多变量模型以鉴定与累积炎症活动相关的因素。
UNASSIGNED:共有22/110例患者(20%)符合LORA标准(≥60岁)。与患有YORA和对照组的患者相比,患有LORA的患者更频繁地患有合并症。与YORA患者相比,更多的LORA患者从发病开始累积高炎症活动[13(59%)与28(31%);p=0.018]和CRP(p=0.039)和IL-6(p=0.045)的高值。RA患者的累积高炎症活动与LORA相关[OR(95%CI)4.69(1.49-10.71);p=0.008],吸烟[OR(95%CI)2.07(1.13-3.78);p=0.017],抗瓜氨酸肽抗体[OR(95%CI)3.24(1.15-9.13);p=0.025],平均健康评估问卷(HAQ)得分[OR(95%CI)2.09(1.03-14.23);p=0.034],和身体活动[OR(95%CI)0.99(0.99-0.99);p=0.010]。第二个模型显示与LORA患者的炎症活动相似。
UNASSIGNED:与YORA患者和健康对照组相比,LORA患者诊断后炎症控制较差,合并症更频繁。
UNASSIGNED: To describe the characteristics of patients between late-onset rheumatoid arthritis (LORA) with young-onset (YORA), and analyze their association with cumulative inflammatory burden.
UNASSIGNED: We performed a nested cohort study in a prospective cohort comprising 110 patients with rheumatoid arthritis (RA) and 110 age- and sex-matched controls. The main variable was cumulative inflammatory activity according to the 28-joint Disease Activity Score with erythrocyte sedimentation rate (DAS28-ESR). High activity was defined as DAS28 ≥ 3.2 and low activity as DAS28 < 3.2. The other variables recorded were inflammatory cytokines, physical function, and comorbid conditions. Two multivariate models were run to identify factors associated with cumulative inflammatory activity.
UNASSIGNED: A total of 22/110 patients (20%) met the criteria for LORA (≥ 60 years). Patients with LORA more frequently had comorbid conditions than patients with YORA and controls. Compared with YORA patients, more LORA patients had cumulative high inflammatory activity from onset [13 (59%) vs. 28 (31%); p = 0.018] and high values for CRP (p = 0.039) and IL-6 (p = 0.045). Cumulative high inflammatory activity in patients with RA was associated with LORA [OR (95% CI) 4.69 (1.49-10.71); p = 0.008], smoking [OR (95% CI) 2.07 (1.13-3.78); p = 0.017], anti-citrullinated peptide antibody [OR (95% CI) 3.24 (1.15-9.13); p = 0.025], average Health Assessment Questionnaire (HAQ) score [OR (95% CI) 2.09 (1.03-14.23); p = 0.034], and physical activity [OR (95% CI) 0.99 (0.99-0.99); p = 0.010]. The second model revealed similar associations with inflammatory activity in patients with LORA.
UNASSIGNED: Control of inflammation after diagnosis is poorer and comorbidity more frequent in patients with LORA than in YORA patients and healthy controls.